Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (31-40 of 184) with videos related to

Pageof 19
Sort By:
Molecular & Cellular Oncology|September 26, 2018
JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemiaCharles E de Bock, Jan Cools
Hemasphere|June 24, 2022
The Updated European Hematology Association Research RoadmapAndreas Engert, Francesco Cerisoli, Jan Cools
Haematologica|August 10, 2012
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220Daphnie Pauwels, Bram Sweron, Jan Cools
Journal of Hematology & Oncology|October 24, 2023
CRISPR screening in hematology research: from bulk to single-cell levelSarah Meyers, Sofie Demeyer, Jan Cools
Expert Review of Hematology|September 21, 2012
Chromosomal aberrations and fusion genes in myeloid malignanciesValentina Gianfelici, Idoya Lahortiga, Jan Cools
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 5, 2005
Resistance to tyrosine kinase inhibitors: calling on extra forcesJan Cools, Chantal Maertens, Peter Marynen
Hemasphere|January 17, 2020
Introducing the HemaSphere Controversies SeriesDennis A Eichenauer, Jan Cools, Andreas Engert
Haematologica|August 5, 2005
Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Peter Marynen, Jan Cools
Plos Medicine|March 2, 2005
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly headJennifer Clark, Jan Cools, D Gary Gilliland
Hemasphere|January 25, 2020
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsInge Govaerts, Kris Jacobs, Roel Vandepoel, et al.
Pageof 19

Showing results (31-40 of 184) with videos related to

Sort By:
Pageof 19
Molecular & Cellular Oncology|September 26, 2018
JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemiaCharles E de Bock, Jan Cools
Hemasphere|June 24, 2022
The Updated European Hematology Association Research RoadmapAndreas Engert, Francesco Cerisoli, Jan Cools
Haematologica|August 10, 2012
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220Daphnie Pauwels, Bram Sweron, Jan Cools
Journal of Hematology & Oncology|October 24, 2023
CRISPR screening in hematology research: from bulk to single-cell levelSarah Meyers, Sofie Demeyer, Jan Cools
Expert Review of Hematology|September 21, 2012
Chromosomal aberrations and fusion genes in myeloid malignanciesValentina Gianfelici, Idoya Lahortiga, Jan Cools
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 5, 2005
Resistance to tyrosine kinase inhibitors: calling on extra forcesJan Cools, Chantal Maertens, Peter Marynen
Hemasphere|January 17, 2020
Introducing the HemaSphere Controversies SeriesDennis A Eichenauer, Jan Cools, Andreas Engert
Haematologica|August 5, 2005
Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Peter Marynen, Jan Cools
Plos Medicine|March 2, 2005
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly headJennifer Clark, Jan Cools, D Gary Gilliland
Hemasphere|January 25, 2020
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 InhibitorsInge Govaerts, Kris Jacobs, Roel Vandepoel, et al.
Pageof 19